Molecular mechanism of liver X receptors in cancer therapeutics.

Liver X receptors (LXRs) are receptors that belong to the nuclear receptor superfamily (NRs). It was originally called the "orphan receptor" when it was firstly discovered. Then it was found to be activated by oxysterol and it was officially named LXRs. LXRs are activated by ligands and bind to the retinol X receptor to form a heterodimer and regulate metabolism. Numerous studies have shown that LXRs are involved in regulating immune function and maintaining immune tolerance. Activating LXRs can also inhibit the tumorigenesis and promote apoptosis of tumor cells, which make LXRs as potential targets in cancer treatment. This review will discuss the recent progress of LXRs from the structure and function of LXRs, the signaling pathway of LXRs, the molecular mechanism of LXRs activation in cancers, and the potential targets of LXRs in cancer therapy.

• Publication year

  2021

• Venue

  Life Science

• Publication date

  2021-03-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lfs.2021.119287PMID 33667512
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LXR activation radiosensitizes non-small cell lung cancer by restricting myeloid-derived suppressor cells.

  2020cited by this paper
• Combinations of LXR and RXR agonists induce triglyceride accumulation in human HepaRG cells in a synergistic manner

  2020cited by this paper
• The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy

  2020cited by this paper
• Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment

  2020cited by this paper
• EGFR/FOXO3A/LXR-α Axis Promotes Prostate Cancer Proliferation and Metastasis and Dual-Targeting LXR-α/EGFR Shows Synthetic Lethality

  2020cited by this paper
• miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder.

  2020cited by this paper
• Liver X receptor inhibits the growth of hepatocellular carcinoma cells via regulating HULC/miR-134-5p/FOXM1 axis.

  2020cited by this paper
• LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription

  2020cited by this paper
• VD3 and LXR agonist (T0901317) combination demonstrated greater potency in inhibiting cholesterol accumulation and inducing apoptosis via ABCA1-CHOP-BCL-2 cascade in MCF-7 breast cancer cells

  2020cited by this paper
• Cholesterol, Oxysterols and LXRs in Breast Cancer Pathophysiology

  2020cited by this paper
• Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl‐xL inhibition

  2019cited by this paper
• Expression of LXR-β, ABCA1 and ABCG1 in human triple-negative breast cancer tissues

  2019cited by this paper
• Active polypeptides from Hirudo inhibit endothelial cell inflammation and macrophage foam cell formation by regulating the LOX-1/LXR-α/ABCA1 pathway.

  2019cited by this paper
• The role of miRNAs in the invasion and metastasis of cervical cancer

  2019cited by this paper
• LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer

  2019cited by this paper
• RASAL1 induces to downregulate the SCD1, leading to suppression of cell proliferation in colon cancer via LXRα/SREBP1c pathway

  2019cited by this paper
• Sequential depletion of myeloid-derived suppressor cells and tumor cells with a dual-pH-sensitive conjugated micelle system for cancer chemoimmunotherapy.

  2019cited by this paper
• LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

  2018cited by this paper
• Treatment of colon cancer with liver X receptor agonists induces immunogenic cell death

  2018cited by this paper
• Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways.

  2018cited by this paper
• Tumor LXR Expression is a Prognostic Marker for Patients with Hepatocellular Carcinoma

  2018cited by this paper
• Abstract 15511: Kruppel-Like Factor 4 Regulation of Cholesterol-25-Hydroxylase and Liver X Receptor Mitigates Atherosclerosis Susceptibility

  2017cited by this paper
• Liver X receptors as potential targets for cancer therapeutics.

  2017cited by this paper
• Liver X receptor as a drug target for the treatment of breast cancer

  2016cited by this paper
• An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.

  2016cited by this paper
• Posttranslational Modifications of Lipid-Activated Nuclear Receptors: Focus on Metabolism

  2016cited by this paper
• The up-regulation of long non-coding RNA CCAT2 indicates a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition.

  2016cited by this paper
• The emerging roles of liver X receptors and their ligands in cancer

  2016cited by this paper
• Targeting liver X receptors in cancer therapeutics

  2015cited by this paper
• Liver X receptor β activation induces pyroptosis of human and murine colon cancer cells

  2014cited by this paper
• Cholesterol metabolism and immunity.

  2014cited by this paper
• Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation.

  2014cited by this paper
• Identification of interferon-γ as a new molecular target of liver X receptor.

  2014cited by this paper
• Antiproliferative Effects and Mechanisms of Liver X Receptor Ligands in Pancreatic Ductal Adenocarcinoma Cells

  2014cited by this paper
• Liver X receptors in lipid metabolism: opportunities for drug discovery

  2014cited by this paper
• Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism

  2013cited by this paper
• 27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology

  2013cited by this paper
• Macrophage apolipoprotein E and proliferation of MCF-7 breast cancer cells: role of LXR.

  2013cited by this paper
• Selective liver X receptor modulators (SLiMs): what use in human health?

  2012cited by this paper
• Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis.

  2012cited by this paper
• Oxysterol receptors, AKT and prostate cancer.

  2012cited by this paper
• LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: relation to proliferation and apoptosis.

  2012cited by this paper
• Liver X Receptor Activation Reduces Angiogenesis by Impairing Lipid Raft Localization and Signaling of Vascular Endothelial Growth Factor Receptor-2

  2012cited by this paper
• ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models

  2012cited by this paper
• IFN‐γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice

  2011cited by this paper
• Targeting liver X receptors in human health: deadlock or promising trail?

  2011cited by this paper
• An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

  2011cited by this paper
• Transcriptional Regulation of Human and Rat Hepatic Lipid Metabolism by the Grapefruit Flavonoid Naringenin: Role of PPARα, PPARγ and LXRα

  2010cited by this paper
• Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses

  2010cited by this paper
• Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells

  2010cited by this paper
• Identification of 5α,6α-Epoxycholesterol as a Novel Modulator of Liver X Receptor Activity

  2010cited by this paper
• Discovery of tertiary sulfonamides as potent liver X receptor antagonists.

  2010cited by this paper
• Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells

  2010cited by this paper
• Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR.

  2009cited by this paper
• Abstract 1367: Tissue-specific Liver X Receptor Activation Promotes Macrophage Reverse Cholesterol Transport in vivo

  2009cited by this paper
• Liver X receptors interfere with cytokine‐induced proliferation and cell survival in normal and leukemic lymphocytes

  2009cited by this paper
• Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants

  2009cited by this paper
• The oxysterol receptor LXR inhibits proliferation of human breast cancer cells.

  2009cited by this paper
• Integration of metabolism and inflammation by lipid-activated nuclear receptors

  2008cited by this paper
• Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells

  2008cited by this paper
• LXR signaling couples sterol metabolism to proliferation in the acquired immune response.

  2008cited by this paper
• Hypercholesterolemia and prostate cancer: a hospital-based case–control study

  2008cited by this paper
• HDL-cholesterol and incidence of breast cancer in the ARIC cohort study.

  2008cited by this paper
• A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer

  2007cited by this paper
• The Liver X Receptor (LXR) and Hepatic Lipogenesis

  2007cited by this paper
• Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor.

  2007cited by this paper
• Nuclear receptors, metabolism, and the circadian clock.

  2007cited by this paper
• LXRS and FXR: the yin and yang of cholesterol and fat metabolism.

  2006cited by this paper
• Liver X receptor agonists ameliorate TNFα-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression

  2006cited by this paper
• Liver X receptors as integrators of metabolic and inflammatory signaling.

  2006cited by this paper
• Riccardin C: A natural product that functions as a liver X receptor (LXR)α agonist and an LXRβ antagonist

  2005cited by this paper
• Diterpenoid, steroid, and triterpenoid agonists of liver X receptors from diversified terrestrial plants and marine sources.

  2005cited by this paper
• A novel LXR-α activator identified from the natural product Gynostemma pentaphyllum

  2005cited by this paper
• Riccardin C: a natural product that functions as a liver X receptor (LXR)alpha agonist and an LXRbeta antagonist.

  2005cited by this paper
• A novel LXR-alpha activator identified from the natural product Gynostemma pentaphyllum.

  2005cited by this paper
• Antiproliferative Effect of Liver X Receptor Agonists on LNCaP Human Prostate Cancer Cells

  2004cited by this paper
• Androgenic Suppression of ATP-binding Cassette Transporter A1 Expression in LNCaP Human Prostate Cancer Cells

  2004cited by this paper
• [Oxysterols: metabolism, biological role and associated diseases].

  2004cited by this paper
• The nuclear oxysterol receptor LXRα is expressed in the normal human breast and in breast cancer

  2004cited by this paper
• Les oxystérols : métabolisme, rôles biologiques et pathologies associées

  2004cited by this paper
• Reciprocal regulation of inflammation and lipid metabolism by liver X receptors

  2003cited by this paper
• Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.

  2003cited by this paper
• Liver X receptor signaling pathways in cardiovascular disease.

  2003cited by this paper
• Direct and Indirect Mechanisms for Regulation of Fatty Acid Synthase Gene Expression by Liver X Receptors*

  2002cited by this paper
• Polyunsaturated Fatty Acids Suppress Sterol Regulatory Element-binding Protein 1c Promoter Activity by Inhibition of Liver X Receptor (LXR) Binding to LXR Response Elements*

  2002cited by this paper
• Overweight, obesity, and cancer risk.

  2002cited by this paper
• Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR

  2001cited by this paper
• LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes.

  2001cited by this paper
• Role of the Cdc25A phosphatase in human breast cancer.

  2000cited by this paper
• The role of orphan nuclear receptors in the regulation of cholesterol homeostasis.

  2000cited by this paper
• Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta.

  1999cited by this paper
• Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha.

  1998cited by this paper
• Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα

  1998cited by this paper
• The LXRs: a new class of oxysterol receptors.

  1998cited by this paper
• Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR.

  1997cited by this paper
• An oxysterol signalling pathway mediated by the nuclear receptor LXRα

  1996cited by this paper
• A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily

  1994cited by this paper
• LIPID CONTENT OF TUMORS.

  1932cited by this paper

• Liver X receptor: A potential target for inflammatory bowel disease and colorectal cancer (Review)

  2025cites this paper
• HDL Nanodiscs Loaded with Liver X Receptor Agonist Decreases Tumor Burden and Mediates Long‐term Survival in Mouse Glioma Model

  2025cites this paper
• Sesamin regulates breast cancer through reprogramming of lipid metabolism

  2025cites this paper
• A Novel Rexinoid Agonist, UAB116, Decreases Metastatic Phenotype in Hepatoblastoma by Inhibiting the Wnt/β-Catenin Pathway via Upregulation of TRIM29

  2025cites this paper
• TTC36 as a prognostic biomarker in nonmetastatic hepatocellular carcinoma: A TCGA-based cohort study

  2025cites this paper
• Nuclear Receptors in Metabolism and Diseases: Mechanistic and Therapeutic Insights.

  2025cites this paper
• Lipid metabolism-related genes in gastric cancer: Exploring oncogenic pathways

  2025cites this paper
• Implication of Oxysterols and Phytosterols in Aging and Human Diseases.

  2024cites this paper
• Circular RNAs and the JAK/STAT pathway: New frontiers in cancer therapeutics.

  2024cites this paper
• Regulatory mechanism underlying liver X receptor effects on the tumor microenvironment, inflammation and tumorigenesis

  2023cites this paper
• Liver X receptors: From pharmacology to nanoparticle-based drug delivery.

  2023cites this paper
• Emerging Insights into Liver X Receptor α in the Tumorigenesis and Therapeutics of Human Cancers

  2023cites this paper
• iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma

  2022cites this paper
• Lipid metabolism in pancreatic cancer: emerging roles and potential targets

  2022cites this paper